Interview Questions Asked in Pharmacovigilance Jobs (With Answers)

 

Introduction: Preparation is the Only Differentiator

In pharmacovigilance interviews across India's CROs and pharmaceutical companies, the same questions appear with remarkable consistency. Hiring managers are not trying to trick you — they are testing whether you have the specific, practical knowledge that the job requires from day one. The candidates who perform best are those who have been trained in environments that mirror the interview itself: structured case exercises, mock assessments, and faculty who explain not just what the answer is but why it is correct. For students who have completed Clinical Research Courses in Pune with pharmacovigilance modules, many of these questions will feel familiar — because a well-designed curriculum prepares you for the interview while it prepares you for the job.

Q1: What are the four minimum criteria for a valid ICSR?

Model Answer: A valid Individual Case Safety Report requires four minimum elements — an identifiable patient, an identifiable reporter, a suspect drug, and an adverse event or outcome. If any one of these four elements is missing, the report cannot be processed as a valid ICSR and follow-up must be initiated to obtain the missing information. This is tested at every level of PV hiring and must be answered without hesitation.

Q2: What is the difference between an adverse event and an adverse drug reaction?

Model Answer: An adverse event is any untoward medical occurrence in a patient receiving a medicinal product, regardless of whether a causal relationship with the drug is suspected. An adverse drug reaction is a response to the drug that is noxious, unintended, and occurs at doses normally used in humans — implying at least a possible causal relationship. In clinical trials, all untoward occurrences are captured as adverse events; the causality assessment that determines whether an AE is classified as an ADR is a separate step in the processing workflow.

Q3: What are the expedited reporting timelines for serious adverse reactions?

Model Answer: For fatal or life-threatening unexpected serious adverse reactions, the expedited reporting timeline is 7 calendar days from the date the sponsor becomes aware, with a follow-up report within 15 days. For all other unexpected serious adverse reactions, the timeline is 15 calendar days. These timelines apply across most major regulatory jurisdictions including CDSCO, FDA, and EMA, and failure to meet them constitutes a significant regulatory compliance violation.

Q4: What is MedDRA and why is it used?

Model Answer: MedDRA — the Medical Dictionary for Regulatory Activities — is the internationally standardised medical terminology used to classify adverse events, medical history, indications, and other medical concepts in regulatory submissions and pharmacovigilance databases worldwide. It is used because it provides a common language that allows adverse event data from different countries, companies, and reporting systems to be compared, aggregated, and analysed in a consistent and meaningful way. It has five hierarchical levels: System Organ Class, High Level Group Term, High Level Term, Preferred Term, and Lowest Level Term.

Q5: What is a SUSAR?

Model Answer: A SUSAR is a Suspected Unexpected Serious Adverse Reaction — a serious adverse event from a clinical trial that is both unexpected (not listed in the reference safety information for the investigational product) and for which the investigator or sponsor considers a causal relationship with the study drug at least a reasonable possibility. SUSARs must be reported to regulatory authorities and ethics committees on an expedited basis — within 7 days for fatal or life-threatening cases and 15 days for all others. Students completing a Pharmacovigilance Course in Pune who also have clinical trial safety training will understand both the clinical trial context in which SUSARs arise and the pharmacovigilance workflow through which they are processed and reported.

Q6: How would you handle a case with missing information?

Model Answer: I would first assess whether the case meets the four minimum validity criteria with the information available. If it does, I would process it as a valid case and initiate a follow-up request to obtain the missing data — documenting the follow-up attempt in the safety database with a defined timeline for response. If the case does not meet minimum validity criteria, I would still log it as an incomplete report and initiate follow-up. The follow-up process, timelines, and documentation requirements are typically defined in the company's pharmacovigilance SOPs and must be followed consistently for every case.

Conclusion: Practice Until the Answers Are Automatic

Pharmacovigilance interviews reward candidates who can answer technical questions accurately, quickly, and confidently — demonstrating that their knowledge is operational, not merely academic. The way to achieve this is through structured practice in a training environment that replicates interview conditions.

For students in Maharashtra who want to walk into a PV interview fully prepared, comprehensive Clinical Research Institute in Pune that include mock interview sessions, practical case exercises, and faculty feedback on technical answers provide the most direct and effective interview preparation available in the region.